News from Nektar Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 22, 2017, 17:07 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2016, on Wednesday, March...


Feb 18, 2017, 19:24 ET Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in...


Jan 05, 2017, 09:00 ET Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 35th Annual...


Nov 14, 2016, 09:00 ET Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies 2016 London...


Nov 09, 2016, 14:30 ET Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented...


Nov 03, 2016, 16:10 ET Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2016. Cash and investments in...


Oct 28, 2016, 08:15 ET Nektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event at the upcoming Society for Immunotherapy of...


Oct 28, 2016, 08:00 ET Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming Society for Immunotherapy of Cancer...


Oct 27, 2016, 16:15 ET Nektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3,...


Oct 19, 2016, 00:52 ET Nektar Therapeutics Prices Public Offering of Shares of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced the pricing of its previously announced underwritten public offering of $175.5...


Oct 17, 2016, 16:01 ET Nektar Therapeutics Announces Public Offering of Shares of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced that it has commenced an underwritten public offering of $175 million of shares of...


Sep 27, 2016, 07:45 ET Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb

 Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical...


Aug 03, 2016, 16:15 ET Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2016. Cash and investments in...


Jul 27, 2016, 17:15 ET Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday,...


Jun 06, 2016, 14:00 ET Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being...


Jun 02, 2016, 18:30 ET Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City

 Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies...


Jun 02, 2016, 16:30 ET Nektar Therapeutics Announces Executive Management Promotions

 Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and...


May 03, 2016, 16:05 ET Nektar Therapeutics Reports Financial Results for the First Quarter of 2016

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2016. Cash and investments in...


Apr 28, 2016, 08:00 ET Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2016, on Tuesday, May 3, 2016,...


Apr 18, 2016, 08:30 ET Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration

 Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for the company's investigational immuno-stimulatory cytokine therapy,...


Mar 03, 2016, 16:15 ET Nektar Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference in Boston, MA

 Nektar Therapeutics (Nasdaq: NKTR)  is scheduled to present at the upcoming Cowen and Company 36th Annual Health Care Conference in...


Mar 01, 2016, 16:10 ET Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2015. Cash and...


Feb 26, 2016, 14:30 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2015 on Tuesday, March 1, 2016, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2015, on Tuesday, March...


Feb 25, 2016, 20:56 ET Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings

 Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with...


Feb 01, 2016, 09:00 ET Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research

 Nektar Therapeutics (Nasdaq: NKTR) today announced the publication in Clinical Cancer Research of pre-clinical findings for NKTR-214. The...